Institutional investors purchased a net $802.8 thousand shares of STML during the quarter ended December 2015. This may signal that the smart money is gaining interest in this company as the 53.84% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
RUSSELL INVESTMENT MANAGEMENT CO... Bought 14.1 Thousand shares of Stemline Therapeutics Inc